Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315885 | 0.85 | OPRM1 (0.51) | KMT2ATSHRHTTMAPK1SMN1; SMN2 | |
| SCHEMBL13501818 | 0.85 | GABRA5 (0.64) | KMT2ASMN1; SMN2MEN1L3MBTL1NPSR1 | |
| SCHEMBL20006960 | 0.84 | ALDH1A1 (0.67) | KMT2ATSHRHTTMAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL317416 | 0.84 | OPRM1 (0.53) | KMT2ATSHRHTTMAPK1SMN1; SMN2 | |
| SCHEMBL13501829 | 0.83 | GABRA5 (0.48) | KMT2ASMN1; SMN2MEN1GABRA5 | |
| SCHEMBL13501828 | 0.83 | CYP1A1 (0.51) | KMT2ASMN1; SMN2GAAMEN1L3MBTL1 | |
| SCHEMBL3977460 | 0.83 | HTT (0.65) | KMT2ATSHRHTTSMN1; SMN2GAA | |
| SCHEMBL352886 | 0.81 | TSHR (0.68) | KMT2ATSHRHTTMAPK1SMN1; SMN2 | |
| SCHEMBL976467 | 0.81 | TSHR (0.68) | KMT2ATSHRHTTMAPK1SMN1; SMN2 | |
| SCHEMBL27722453 | 0.81 | KMT2A (0.76) | KMT2ATSHRHTTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| CN-100384418-C | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | NOVARTIS AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| EP-1418912-B1 | ISOXAZOLOPYRIDINONES | NOVARTIS AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-7087756-B2 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2006-08-08 | — | — | US | disclosed |
| CN-1635889-A | Isoxazolopyridinones and their use in the treatment of parkinson's disease | NOVARTIS AG (CH) | 2005-07-06 | — | — | CN | disclosed |
| US-20040248893-A1 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1418912-A2 | ISOXAZOLOPYRIDINONES | Novartis AG (CH) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003015780-A2 | ISOXAZOLOPYRIDINONES AND USE THEREOF IN THE TREATMENT OF PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | KMT2A 2389/4885TSHR 2190/4885HTT 2807/4885 |
| US-20040248893-A1 | Isoxazolopyridinones | XDH, NPY1R, TBXA2R | KMT2A 2514/4885TSHR 874/4885HTT 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.